LaserSight To Seek Approval For Widespread Laser-K Commercialization
This article was originally published in The Gray Sheet
Executive Summary
LaserSight will need to conduct a study including patients from a few sites as part of a single premarket approval supplement to support widespread commercialization of Frederic Kremer's Laser-K in situ keratomelius (LASIK) excimer laser, FDA staffers say.